MedWorm: Cervical Cancer Vaccine

Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males--Advisory Committee on Immunization Practices (ACIP), 2011 [From the Centers for Disease Control and Prevention]

JAMA — Tue, 07 Feb 2012 05:00:00 +0100

(Source: JAMA)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Human Papillomavirus Vaccination Practices Among Providers in Indian Health Service, Tribal and Urban Indian Healthcare Facilities

Journal of Women — Mon, 06 Feb 2012 21:47:50 +0100

Journal of Women's Health , Vol. 0, No. 0. (Source: Journal of Women)

Five Years After HPV Vaccine Law, Virginia Remains Split

Drugs.com - Pharma News — Mon, 06 Feb 2012 13:02:59 +0100

Five Years After HPV Vaccine Law, State Remains Split [Virginian - Pilot] From Virginian - Pilot (February 5, 2012) By Elizabeth Simpson | The Virginian-Pilot Tonya McKinney was so intent on her daughter receiving the human papillomavirus... (Source: Drugs.com - Pharma News)

In latest vaccine marketing fraud, CDC says Gardasil shots should be 'routine' for boys

NaturalNews.com — Mon, 06 Feb 2012 06:00:00 +0100

Every male between the ages of 11 and 21 should get a Gardasil vaccine for cervical cancer, and those between the ages of 13 and 21 should also get "catch-up" shots later down the road. This is only the opinion of the U.S. Centers for Disease Control and Prevention's... (Source: NaturalNews.com)

US Pediatricians Recommend Routine HPV Vaccination For Boys

Health News from Medical News Today — Fri, 03 Feb 2012 20:00:00 +0100

As part of a revised standard published this week, the American Academy of Pediatrics says boys should be routinely vaccinated against the human papillomavirus (HPV), a common virus that is spread through sexual contact. Although there are dozens of types of HPV, vaccines can protect both male and females against some of the more common types that can lead to disease and cancer... (Source: Health News from Medical News Today)

National Briefing | Health: Officials Recommend the HPV Vaccine for All Boys

NYT — Fri, 03 Feb 2012 19:20:07 +0100

Federal health officials recommended on Thursday that all boys be routinely vaccinated against infection with human papillomavirus, or HPV. (Source: NYT)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

HPV vaccine now recommended for all boys, CDC says

Health News: CBSNews.com — Fri, 03 Feb 2012 19:18:30 +0100

At least 50 percent of sexually active men and women get will get infected with human papillomavirus at some point, according to CDC (Source: Health News: CBSNews.com)

Well: HPV Vaccine Now Recommended for Boys, Hepatitis B Vaccine for Diabetes

NYT Health — Fri, 03 Feb 2012 03:29:32 +0100

Federal health officials recommended this week that all boys be routinely vaccinated against human papillomavirus, or HPV, and that people with diabetes be vaccinated against hepatitis B. (Source: NYT Health)

National Briefing | Health: Officials Recommend the HPV Vaccine for All Boys

NYT Health — Fri, 03 Feb 2012 01:10:05 +0100

Federal health officials recommended on Thursday that all boys be routinely vaccinated against infection with human papillomavirus, or HPV. (Source: NYT Health)

Well Blog: HPV Vaccine Now Recommended for Boys, Hepatitis B Vaccine for Diabetes

NYT Health — Thu, 02 Feb 2012 16:59:25 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

SaneVax writes open letter to Kathleen Sebelius: Rescind approval of Gardasil due to lack of efficacy during post-licensure monitoring

NaturalNews.com — Thu, 02 Feb 2012 06:00:00 +0100

According to a recently published, industry-sponsored study conducted on 12,852 young women, HPV vaccination was found to reduce HPV-16 infections a mere 0.6% in vaccinated women versus unvaccinated women. At the same time, other high-risk (carcinogenic) HPV infections... (Source: NaturalNews.com)

HPV vaccines (Gardasil) now pushed onto boys in Canada

NaturalNews.com — Thu, 02 Feb 2012 06:00:00 +0100

There is still a whole lot of money to be made from pushing human papillomavirus (HPV) vaccines on young people around the world. But in order to accomplish this, the market for the vaccines, which include Merck & Co.'s Gardasil and GlaxoSmithKline's Cervarix, must be... (Source: NaturalNews.com)

HPV vaccine recommended for boys

Health Facts and Fears — Thu, 02 Feb 2012 05:00:00 +0100

Both the Centers for Disease Control and Prevention and the American Academy of Pediatrics are now advising parents to vaccinate their boys against the human papillomavirus (HPV), especially before they become sexually active. (Source: Health Facts and Fears)

[Correspondence] Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine

The Lancet Oncology — Wed, 01 Feb 2012 05:00:00 +0100

The 4-year end-of-study analysis of the PATRICIA trial published in The Lancet Oncology adds to findings of previous interim analyses. In this trial, Lehtinen and colleagues assessed the efficacy of a bivalent human papillomavirus (HPV) vaccine, administered to 18 644 healthy women aged 15–25 years, for reduction of high-grade cervical intraepithelial neoplasia (CIN3+). (Source: The Lancet Oncology)

HPV Vaccine Policy: At Odds With Evidence-Based Medicine?HPV Vaccine Policy: At Odds With Evidence-Based Medicine?

Medscape Today Headlines — Tue, 31 Jan 2012 16:30:50 +0100

According to a new study, there is a major discrepancy in claims regarding the safety and efficacy of the human papillomavirus (HPV) vaccines. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

'Oral cancer risk' in men as HPV rates higher

NHS News Feed — Mon, 30 Jan 2012 09:57:00 +0100

Conclusion This was a relatively large cross-sectional study that estimated the number of oral HPV infections in the US among 14 to 69 year olds. These estimates cannot be directly generalised to the UK. The researchers say that their data provide evidence that oral HPV infection is mainly sexually transmitted. This is because infection was uncommon among participants with no previous sexual partners, but was up to eight times higher among those with previous partners, and increased significantly as the number of partners increased. The researchers do point out, however, that their study did not collect information on possible non-sexual transmission methods. While policy decisions regarding HPV infection generally focus on genital HPV among females, this research demonstrated that, at lea...

Knowledge, attitude and practice in primary and secondary cervical cancer prevention among young adult Italian women.

Vaccine — Mon, 30 Jan 2012 05:00:00 +0100

Authors: Donati S, Giambi C, Declich S, Salmaso S, Filia A, Atti ML, Alibrandi MP, Brezzi S, Carozzi F, Collina N, Franchi D, Lattanzi A, Meda M, Minna MC, Nannini R, Gallicchio G, Bella A, Abstract In Italy since 2007 vaccination against human papillomavirus (HPV) is offered to 11-year-old females, whereas vaccination for older age groups is still a matter of debate. To assess Italian young women's knowledge, attitudes and practice regarding primary and secondary cervical cancer prevention a cross-sectional study among young women aged 18-26 years was conducted in 2008. The survey collected information on in-depth awareness and knowledge regarding Pap testing, HPV infection, HPV vaccine and cervical cancer. The response rate was 57.7% with a wide range of variability (34-84%) amo...

HPV Vaccine Not Linked To Autoimmune Disorders, Study

Health News from Medical News Today — Sun, 29 Jan 2012 00:00:00 +0100

A two-year study of nearly 190,000 girls and women, finds that Gardasil, the human papillomavirus (HPV) vaccine made by Merck & Co, does not trigger autoimmune disorders such as lupus, rheumatoid arthritis, type 1 diabetes and multiple sclerosis. The results are published in the Journal of Internal Medicine. Study lead author Dr Chun Chao, a research scientist at the Kaiser Permanente Department of Research & Evaluation in Pasadena, California, said in a statement released on Friday, that: "This kind of safety information may help parents with vaccination decisions... (Source: Health News from Medical News Today)

No Increase in Autoimmune Conditions From Use of HPV VaccineNo Increase in Autoimmune Conditions From Use of HPV Vaccine

Medscape Today Headlines — Fri, 27 Jan 2012 23:31:42 +0100

In a large population of young women aged 9 to 26 years receiving quadrivalent human papillomavirus vaccine, researchers found no increase in new-onset cases for 16 autoimmune conditions surveyed. Medscape Medical News (Source: Medscape Today Headlines)

Study: No link between HPV vaccine and autoimmune disorders

USATODAY.com Health — Fri, 27 Jan 2012 21:30:42 +0100

The human papillomavirus (HPV) vaccine Gardasil does not trigger autoimmune disorders according to a new study. (Source: USATODAY.com Health)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Oral HPV Infection: Higher in Men, Transmitted by SexOral HPV Infection: Higher in Men, Transmitted by Sex

Medscape Today Headlines — Fri, 27 Jan 2012 13:43:46 +0100

A much higher incidence of human papillomavirus (HPV) in men than women raises the question of whether boys should be getting the HPV vaccine in addition to girls. Medscape Medical News (Source: Medscape Today Headlines)

Men At Greater Risk For Oral HPV Infection, HPV-Related Cancers

Health News from Medical News Today — Fri, 27 Jan 2012 12:00:00 +0100

Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Human papillomavirus, or HPV, has recently been linked to some types of head and neck cancer that are becoming more prominent in the United States, mostly among men... (Source: Health News from Medical News Today)

2-Year Study Finds Gardasil Does Not Trigger Autoimmune Conditions After Vaccination

Health News from Medical News Today — Fri, 27 Jan 2012 08:00:00 +0100

Gardasil, the human papillomavirus vaccine that is now recommended for male and female adolescents and young adults, does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, type 1 diabetes or multiple sclerosis after vaccination in young women, according to a new study in the Journal of Internal Medicine. Kaiser Permanente researchers used electronic health records to conduct an observational safety study of 189,629 females aged 9 to 26 years old in California who were followed for six months after receiving each dose of the quadrivalent HPV vaccine in 2006-2008... (Source: Health News from Medical News Today)

inducTION of mage‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinoma

Head and Neck — Fri, 27 Jan 2012 05:00:00 +0100

ConclusionThis treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA‐II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012 (Source: Head and Neck)

Oral Cancer: Another target ripe for HPV vaccine

Health Facts and Fears — Fri, 27 Jan 2012 05:00:00 +0100

Oropharyngeal cancer, which affects the throat, tongue, soft palate, and tonsils, has become increasingly common among men in the U.S. Because a distinct form of it is caused primarily by HPV (human papillomavirus), a recent study set out to determine the prevalence of oral HPV infection. attack. (Source: Health Facts and Fears)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

[Correspondence] Genital HPV types in Australia

The Lancet Infectious Diseases — Thu, 26 Jan 2012 23:05:13 +0100

We were intrigued by Edoardo Tartaglia and colleagues' use of a small sample of human papillomavirus (HPV) typing data of unknown representativeness to scrutinise the decline in genital warts reported in Australia after HPV vaccination. They suggest that the decline could be less than anticipated by international data because genital warts in Australia might be caused predominantly by non-HPV vaccine types, implying that the cause of genital warts in Australia could be different to that in every other country studied. (Source: The Lancet Infectious Diseases)

Well: Oral HPV More Common in Men Than Women

NYT — Thu, 26 Jan 2012 19:30:23 +0100

About one in 15 Americans is infected with oral human papillomavirus, a sexually transmitted virus that causes throat cancers, and the disease is especially common among men, new research shows. (Source: NYT)

Vital Signs: Patterns: Oral HPV More Common in Men Than Women

NYT Health — Thu, 26 Jan 2012 19:30:23 +0100

Vital Signs: Risks: Oral HPV More Common in Men Than Women

NYT Health — Thu, 26 Jan 2012 19:30:23 +0100

7% Of Americans Have Oral HPV

Health News from Medical News Today — Thu, 26 Jan 2012 17:00:00 +0100

A study published online in JAMA on Thursday suggests 7% of men and women in the US carry the Human papillomavirus (HPV), the virus that causes a distinct form of cancer that affects the part of the throat that sits at the back of the mouth. The study suggests oral HPV infection is predominantly sexually transmitted, and estimates that men are nearly three times more likely to have the virus than women. Maura L. Gillison, Professor in the College of Medicine at Ohio State University (OSU), and others carried out the study... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Self-HPV Testing Could Be An Effective Cervical Cancer Screening Method

Health News from Medical News Today — Thu, 26 Jan 2012 17:00:00 +0100

A study published January 23 in the Journal of the National Cancer Institute , has found that self-HPV (human papillomavirus) testing, in low-resource settings, may be a more effective way to screen for cervical cancer than liquid-based cytology (LBC) and visual inspection with acetic acid (VIA). Cervical cancer is one of the most prevalent cancers found in women. Each year, around 530,000 women are diagnosed with the disease, resulting in an estimated 275,000 deaths... (Source: Health News from Medical News Today)

Study Finds No Link Between HPV Vaccine and Autoimmune Disorders

MedlinePlus Health News — Thu, 26 Jan 2012 17:00:00 +0100

No risk seen among nearly 190,000 Gardasil recipients in company-funded review Source: HealthDay Related MedlinePlus Pages: Autoimmune Diseases, HPV, Immunization (Source: MedlinePlus Health News)

Well: Oral HPV More Common in Men Than Women

NYT Health — Thu, 26 Jan 2012 15:49:41 +0100

Indications Of A Benefit In Primary HPV Testing

Health News from Medical News Today — Thu, 26 Jan 2012 08:00:00 +0100

Precursors of cervical cancer can be detected and treated earlier / Risk of over-treatment Studies currently available provide indications and a "hint" that precursors of cervical cancer can be detected and treated earlier, and consequently tumours occur less often, in women who underwent testing for human papillomavirus (HPV). In this context, an HPV test can be used alone or in addition to a Papanicolaou test (Pap smear). However, both screening procedures also carry a risk of harm in the form of unnecessary treatments after testing (over-treatment)... (Source: Health News from Medical News Today)

Study Finds No Link Between HPV Vaccine and Autoimmune Disorders

Pharmacy News - Doctors Lounge — Thu, 26 Jan 2012 05:00:00 +0100

No risk seen among nearly 190,000 Gardasil recipients in company-funded review (Source: Pharmacy News - Doctors Lounge)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Mass psychogenic illness or brain damage of unknown origin?

NaturalNews.com — Wed, 25 Jan 2012 06:00:00 +0100

Vaccine Forum Turns Emotional 12 Girls in Le Roy New York Develop Tics - Gardasil Related? Diagnosed as Mass Hysteria Mass Hysteria? Myasshysteria Saying that these girls have conversion disorder takes all females back 100 years. (I.e. Females tend to be "hysterical... (Source: NaturalNews.com)

Kaiser Permanente study finds Gardasil does not trigger autoimmune conditions after vaccination

EurekAlert! - Medicine and Health — Wed, 25 Jan 2012 05:00:00 +0100

(Kaiser Permanente) Gardasil, the human papillomavirus vaccine that is now recommended for male and female adolescents and young adults, does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, Type 1 diabetes or multiple sclerosis after vaccination in young women, according to a new study in the Journal of Internal Medicine. (Source: EurekAlert! - Medicine and Health)

Human Papillomavirus antibody reference reagents for post-vaccine surveillance serology.

Clinical and Vaccine Immunology — Wed, 25 Jan 2012 05:00:00 +0100

Authors: Bissett SL, Wilkinson D, Tettmar KI, Jones N, Stanford E, Panicker G, Faust H, Borrow R, Soldan K, Unger ER, Dillner J, Minor P, Beddows S Abstract Suitably-controlled sero-surveillance surveys are essential for evaluating Human Papillomavirus (HPV) immunization programmes. A panel of plasma samples from 18 year old females was assembled, the majority being from bivalent vaccinees. Antibody specificities were evaluated by three independent laboratories and 3 pools were created that displayed either no antibodies to any HPV type tested, intermediate or high antibody levels to HPV16, HPV18, HPV31 and HPV45. These pools will be useful as control reagents for HPV serology. PMID: 22278326 [PubMed - as supplied by publisher] (Source: Clinical and Vaccine Immunology)

Are viruses associated with human breast cancer? Scrutinizing the molecular evidence

Breast Cancer Research and Treatment — Tue, 24 Jan 2012 18:09:20 +0100

Abstract The three viruses most studied as possible causes of human breast cancer are mouse mammary tumor virus-like sequences (MMTV-LS), Epstein-Barr virus (EBV), and oncogenic (high risk) types of human papilloma virus (HPV). The first step in fulfilling traditional criteria for inferring that a cancer is caused by a virus is to demonstrate the virus in the affected tissue. Molecular techniques, compared to host antibody assessment and immunohistochemistry, are the most definitive in establishing viral presence. Results of 85 original molecular research investigations to detect one or more of the three viruses have been extremely divergent with no consensus reached. We evaluated the methodology of these studies for the following: type of molecular assay, DNA/RNA quality ...

Cervical Cancer Screening Via Self-Collection

Health News from Medical News Today — Tue, 24 Jan 2012 10:00:00 +0100

Human papillomavirus (HPV) testing of self-collected specimens may be a more effective way to screen for cervical cancer in low-resource settings compared to visual inspection with acetic acid (VIA) and liquid-based cytology (LBC), according to a study published in the Journal of the National Cancer Institute. Cervical cancer is the third most common cancer found in women with approximately 530,000 new cases each year resulting in an estimated 275,000 deaths... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

Journal of Adolescent Health — Sun, 22 Jan 2012 06:55:03 +0100

Conclusions: In adolescent girls, the HPV-16/18 AS04-adjuvanted vaccine produces anti-HPV-16 and anti-HPV-18 antibody titers that are maintained for up to 4 years at higher levels than those in young women in whom vaccine efficacy against cervical lesions was demonstrated. (Source: Journal of Adolescent Health)

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Journal of Adolescent Health — Sun, 22 Jan 2012 06:51:27 +0100

Conclusions: Females within the HPV vaccine-eligible age-group (9–26 years) had a range of dual HPV-16 DNA and serology negativity from 81%–87%, whereas 90%–98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination. (Source: Journal of Adolescent Health)

Results in a New Study Published in the Annals of Medicine Show...

PRWeb: Medical Pharmaceuticals — Sat, 21 Jan 2012 05:56:11 +0100

The publication of the startling results of a Canadian study involving the effectiveness of the Human Papillomavirus (HPV) vaccine against cervical cancer demonstrate that vaccine policy and...(PRWeb January 18, 2012)Read the full story at http://www.prweb.com/releases/2012/1/prweb9112116.htm (Source: PRWeb: Medical Pharmaceuticals)

Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

BMC Cancer — Fri, 20 Jan 2012 05:00:00 +0100

Conclusions: The overall estimated epidemiological burden of HPV-related cancers and non-malignant diseases is high in men in Europe. Approximately 30% of all new cancer cases attributable to HPV16/18 that occur yearly in Europe were estimated to occur in men. As in women, the vast majority of HPV-positive cancer in men is related to HPV16/18, while almost all HPV-related non-malignant diseases are due to HPV6/11. A substantial number of these malignant and non-malignant diseases may potentially be prevented by quadrivalent HPV vaccination. (Source: BMC Cancer)

Acceptability and uptake of HPV vaccine in Argentina before its inclusion in the immunization program: A population-based survey.

Vaccine — Thu, 19 Jan 2012 05:00:00 +0100

The objective was twofold: first to analyze socio-demographic determinants of women's knowledge on HPV vaccine and secondly, determinants of actual HPV vaccine uptake and acceptability in Argentina after the above-mentioned vaccine advertising shown in mass media in the year 2008. We analyzed vaccine uptake/acceptability separately for women and for their daughters aged 9-15, and willingness to vaccinate one's daughter younger than 9 to receive future HPV vaccination. Results of the 1200 women interviewed, 438 women (36.5%) knew the HPV vaccine and 303 (25%) remembered the mass media advertisement about HPV vaccination. When asked whether she would get vaccinated after having seen/heard the advertisement, around 75% (n=226) of women answered surely/probably yes. No significant differences ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Reported Adverse Events in Young Women Following Quadrivalent Human Papillomavirus Vaccination

Journal of Women — Thu, 19 Jan 2012 04:10:01 +0100

Journal of Women's Health , Vol. 0, No. 0. (Source: Journal of Women)

Girls see need for safe sex even after HPV vaccination

Modern Medicine Contemporary Pediatrics — Wed, 18 Jan 2012 06:37:38 +0100

Adolescent girls believe that they are at less risk for human papillomavirus (HPV) infection after receiving their first HPV vaccination but also overwhelmingly believe in the need for continued safe sex behavior. One-fourth, however, perceive themselves to be at a lower risk for other sexually transmitted infections (STIs) after their first HPV vaccination. Find out why health care providers must talk to girls and their mothers about the limitations of HPV vaccine efficacy and the lack of protection from other STIs. (Source: Modern Medicine Contemporary Pediatrics)

Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.

BJOG : An International Journal of Obstetrics and Gynaecology — Wed, 18 Jan 2012 05:00:00 +0100

Conclusions Increasing the interval between screening rounds and changing the primary test from cytology to HPV testing can improve the effectiveness and decrease the costs of cervical cancer screening in the Netherlands. PMID: 22251259 [PubMed - as supplied by publisher] (Source: BJOG : An International Journal of Obstetrics and Gynaecology)

Cost‐effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing

BJOG: An International Journal of Obstetrics and Gynaecology — Wed, 18 Jan 2012 05:00:00 +0100

Conclusions Increasing the interval between screening rounds and changing the primary test from cytology to HPV testing can improve the effectiveness and decrease the costs of cervical cancer screening in the Netherlands. (Source: BJOG: An International Journal of Obstetrics and Gynaecology)

Girls see need for safe sex even after HPV vaccination

Modern Medicine — Wed, 18 Jan 2012 00:35:50 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

Gynecologic Cancer

Hematology/Oncology Clinics of North America — Tue, 17 Jan 2012 12:47:50 +0100

Like many areas in oncology, gynecologic oncology has made several important recent advances in both the prevention and the treatment of reproductive malignancies. New knowledge related to risk factors for endometrial and ovarian cancer has led to novel strategies to reduce risks through diet, contraception choices, and other factors. Important advances have also occurred in the understanding of genetic risks for gynecologic cancers and genetic testing can now identify individuals at substantial risk. Patients at genetic risk can reduce their risk through the use of oral contraception and other choices if they have not completed their families or undergo definitive prophylactic surgery when they no longer desire future pregnancies. Cervical cancer is an area of particular advancement in pr...

Help prevent cervical cancer with HPV vaccine

Baylor College of Medicine News — Tue, 17 Jan 2012 05:00:00 +0100

Getting the human papillomavirus, or HPV, vaccine provides an important preventative benefit against cervical cancer, said a gynecologic oncologist from Baylor College of Medicine . "Disease prevention and early detection are key in the battle against cancer," said Dr. Celestine Tung, an assistant professor in the department of obstetrics and gynecology in the division of gynecologic oncology at BCM. "With cervical cancer, now we have a way to prevent it with the HPV vaccine." HPV and cervical cancer Approximately 95 percent of cervical cancers are associated with HPV infections, and between 70 to 80 percent of cervical cancers are related to HPV 16 and HPV 18 viral subtypes or strains, Tung said. HPV is the most common sexually transmitted infection affecting between 3...

Monitoring HPV type-specific prevalence over time through clinic-based surveillance: A perspective on vaccine effectiveness.

Vaccine — Tue, 17 Jan 2012 05:00:00 +0100

Authors: Gaffga NH, Flagg EW, Weinstock HS, Shlay JC, Ghanem KG, Koutsky LA, Kerndt PR, Hsu KK, Unger ER, Datta SD Abstract We investigated the feasibility of monitoring trends in prevalence of vaccine-preventable human papillomavirus (HPV) types in different clinic populations. We collected cervical specimens from women presenting to family planning, primary care, and sexually transmitted disease (STD) clinics for routine pap smears in five US cities during 2003-2005. We performed HPV genotyping and calculated annual type-specific prevalences; pre-vaccine era prevalence was highest for HPV 16 (6.0; 95% confidence interval [CI] 5.5-6.6%) and annual prevalences for vaccine-preventable types were stable, with few exceptions, after controlling for clinic type, age group, and city. Wit...

Systemic lupus erythematosus following HPV immunization or infection?

Lupus — Sun, 15 Jan 2012 14:30:03 +0100

This report describes three patients with either newly diagnosed systemic lupus erythematosus (SLE) or SLE flare, following vaccination for human papilloma virus (HPV). Case 1: A 17-year-old female completed two doses of HPV vaccine uneventfully. Two months later, she developed arthralgias with pruritic rashes on both lower extremities, later accompanied by livedo reticularis, bipedal edema with proteinuria, anemia, leucopenia, hypocomplementemia and high titers of anti-nuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA). Kidney biopsy showed International Society of Nephrology/Renal Pathology Society Class III lupus nephritis. She was started on high dose steroids followed by pulse cyclophosphamide therapy protocol for lupus nephritis, and subsequently went into remission. Ca...

Reported Adverse Events in Young Women Following Quadrivalent Human Papillomavirus Vaccination

Journal of Women — Fri, 13 Jan 2012 04:13:28 +0100

Journal of Women's Health , Vol. 0, No. 0. (Source: Journal of Women)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Awareness and acceptability of human papillomavirus vaccine: An application of the instrumental variables bivariate probit model

BMC Public Health - Latest articles — Fri, 13 Jan 2012 03:50:22 +0100

Conclusions: Among populations who are not currently aware of the HPV vaccine, the potential impact of raising awareness on acceptability of HPV vaccination is substantial. This finding provides additional support to strengthening public health programs that increase awareness and policy efforts that address barriers to HPV vaccination. (Source: BMC Public Health - Latest articles)

Race and sexual behavior predict uptake of the human papillomavirus vaccine.

Health Psychology — Mon, 09 Jan 2012 05:00:00 +0100

Conclusion: Racial disparities in use of preventive interventions such as the HPV vaccine exist. Lack of information about public financing of the vaccine, timing of vaccination relative to sexual activity, and perceptions of preventive value may limit uptake among those at highest risk for infection and negative sequelae from infection. Further research to probe knowledge and attitudes toward HPV vaccination and the impact of the media on vaccine initiation and uptake may reveal specific targets of intervention. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (Source: Health Psychology)

Reducing HPV Infection - Single-Sex Vaccination Has Best Effect

Health News from Medical News Today — Thu, 05 Jan 2012 16:00:00 +0100

According to a study in PLoS Medicine, the most effective strategy to protect against human papillomavirus (HPV) is single-sex vaccination. They also found that it was preferable to vaccinate females instead of men, given that females are the sex with the highest prevaccine prevalence of HPV infection. Johannes Bogaards, of the VU University in the Netherlands and his team decided to assess whether vaccinating either just females or males, or both sexes would be the best approach to achieve the most effective reduction of sexually transmitted infections amongst the general population... (Source: Health News from Medical News Today)

Prevalence of infection by different genotypes of human papillomavirus in women with cervical pathology.

Gynecologic Oncology — Thu, 05 Jan 2012 05:00:00 +0100

CONCLUSIONS: In the population we studied, the proportion of women with infection by different genotypes of HPV 16 and HPV 18 was high. This finding confirms the need for further studies to compare the efficacy and protection of current vaccines against intraepithelial lesions and cervical cancer. PMID: 22226808 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)

Girls Who Get HPV Vaccine Still Value Safe Sex (CME/CE)

MedPage Today Infectious Disease — Wed, 04 Jan 2012 13:00:00 +0100

(MedPage Today) -- Most girls who receive the human papillomavirus (HPV) vaccine don't take it as a license for riskier sexual behavior, researchers reported. (Source: MedPage Today Infectious Disease)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Medicaid reimbursement and the uptake of adolescent vaccines.

Vaccine — Wed, 04 Jan 2012 05:00:00 +0100

CONCLUSIONS: Our results suggest that, contrary to what has been shown for childhood vaccines, raising Medicaid reimbursement rates may not improve adolescent vaccine utilization. Instead, other policy changes may be more effective, such as expansion of VFC programs into universal purchase programs, further implementation of school-based vaccine mandates and efforts to raise preventive care visits among adolescents. PMID: 22226859 [PubMed - as supplied by publisher] (Source: Vaccine)

Adolescent Perceptions of Risk and Need for Safer Sexual Behaviors After First Human Papillomavirus Vaccination [Article]

Archives of Pediatrics — Mon, 02 Jan 2012 05:00:00 +0100

Conclusions Few adolescents perceived less need for safer sexual behaviors after the first HPV vaccination. Education about HPV vaccines and encouraging communication between girls and their mothers may prevent misperceptions among these adolescents. (Source: Archives of Pediatrics)

[Comment] Success of HPV vaccination is now a matter of coverage

The Lancet Oncology — Sun, 01 Jan 2012 05:00:00 +0100

In a pair of articles in The Lancet Oncology, Lehtinen and colleagues and Wheeler and colleagues present 4-year end-of-study data from a trial of a prophylactic human papillomavirus (HPV)-16/-18 vaccine (Cervarix, GlaxoSmithKline) in young women aged 15–25 years. From a public-health perspective, these studies have several important contributions. (Source: The Lancet Oncology)

[Errata] Erratum

The Lancet Oncology — Sun, 01 Jan 2012 05:00:00 +0100

Schiffman M, Wacholder S. Success of HPV vaccination is now a matter of coverage. Lancet Oncol 2012;13: 10–12—In this Comment (published online Nov 9, 2011), the last sentence of the sixth paragraph incorrectly lists HPV-35 as one of the oncogenic HPV types covered by the new nine-type Gardasil vaccine; the list should include HPV-45 instead. This correction has been made to the online version as of Jan 3, 2012. (Source: The Lancet Oncology)

[Articles] Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

The Lancet Oncology — Sun, 01 Jan 2012 05:00:00 +0100

We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults). (Source: The Lancet Oncology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

[Articles] Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

The Lancet Oncology — Sun, 01 Jan 2012 05:00:00 +0100

SummaryBackgroundWe evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis after 4 years of follow-up in PATRICIA (PApilloma TRIal against Cancer In young Adults).MethodsHealthy women aged 15–25 years with no more than six lifetime sexual partners were included in PATRICIA irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to HPV-16/18 vaccine or a control hepatitis A vaccine, via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. (Source: The Lancet Oncology)

Impact of HPV Vaccine Availability on Uptake

The Journal for Nurse Practitioners — Sun, 01 Jan 2012 05:00:00 +0100

Abstract: Purpose: To evaluate the impact of human papillomavirus (HPV) vaccine availability on uptake among 19- to 26-year-old female patients of Planned Parenthood of Mid and South Michigan before and after the vaccine became available at the health centers. Results: Availability of the HPV vaccine increased vaccine uptake from 11% before clinic availability to 16% after availability. Accessibility, including cost and provider recommendation, may have influenced uptake. Implications: Improving availability of the HPV vaccine, while helpful, is not sufficient for a substantial increase in uptake. Issues of accessibility, including cost and provider recommendation, must also be addressed. (Source: The Journal for Nurse Practitioners)

The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise

Pharmacoepidemiology and Drug Safety — Sun, 01 Jan 2012 05:00:00 +0100

ABSTRACTIn 2009, the Department of Health and Human Services created the new Post‐Licensure Rapid Immunization Safety Monitoring (PRISM) program, which used data from national health insurance plans and immunization registries to monitor the safety of the H1N1 influenza vaccine. PRISM has now been integrated into the FDA's Mini‐Sentinel pilot program. It strengthens the federal vaccine safety enterprise in two important ways. First, PRISM monitors the largest US general population cohort designated for active surveillance of vaccine safety. Second, PRISM links data from health plans with data from state and city immunization registries, which were a crucial source of exposure data in the H1N1 vaccine evaluation. The Mini‐Sentinel data that support PRISM are updated quarterly, and PRI...

Low risk of type‐specific carcinogenic HPV re‐appearance with subsequent cervical intraepithelial neoplasia grade 2/3

International Journal of Cancer — Sat, 31 Dec 2011 05:00:00 +0100

AbstractCarcinogenic human papillomavirus (HPV) infections are very common after sexual debut and nearly all become undetectable (“clear”) within a few years. Following clearance, the long‐term risks of type‐specific HPV re‐appearance and subsequent risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) are not well defined.In the 7‐year, population‐based cohort study in Guanacaste, Costa Rica, we studied how often type‐specific carcinogenic HPV infections re‐appeared after clearance, and how often re‐appearance led to CIN2+. We considered 1740 carcinogenic HPV infections detected by MY09/11 PCR among 2805 women (18‐91 years old, median 34) who were actively followed at 6‐ or 12‐ month intervals. We identified women with 1 or more type‐specific HPV ...

Scientists buzz Simon Cowell for promoting pseudoscience

Guardian Unlimited Science — Wed, 28 Dec 2011 07:30:00 +0100

Sense About Science publishes its annual review of celebrities' misleading claims, including Cowell's intravenous vitaminsWhere there's a celebrity, there's often a fad diet, miracle crystal bracelet or misunderstanding about science. In 2011, Simon Cowell thought it was best to get his vitamins delivered intravenously, American TV host Bill O'Reilly reckoned the Earth's tides were a mystery, and Gwyneth Paltrow championed expensive detox treatments.These celebrity missteps, and many others, are highlighted in the sixth annual review published by the charity Sense About Science (SAS). "We're seeing changes – people are contacting us, medical charities are briefing their celebrities more and working with us to follow up dangerous advice, and we now have over 5,000 scientists and hundreds ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Vital Signs: No Link Is Seen Between HPV Vaccine and Girls’ Sexual Risks

NYT Health — Mon, 26 Dec 2011 18:30:37 +0100

A survey has found that girls ages 15 to 19 who are vaccinated against human papillomavirus, or HPV, are no more likely to be sexually active. (Source: NYT Health)

HPV Vaccine Does Not Alter Sexual Behavior

Health News from Medical News Today — Sat, 24 Dec 2011 08:00:00 +0100

According to a national study by The Centers for Disease Control & Prevention published in the American Journal of Preventive Medicine, contrary to some people's belief, young women receiving recommended vaccinations for the prevention of human papillomavirus (HPV) infection and related cancers do not engage in more sexually risky behavior. Nicole C. Liddon, Ph.D... (Source: Health News from Medical News Today)

Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP), 2011

CDC Morbidity and Mortality Weekly Report — Sat, 24 Dec 2011 04:35:49 +0100

(Source: CDC Morbidity and Mortality Weekly Report)

Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011.

MMWR Morb Mortal Wkl... — Fri, 23 Dec 2011 05:00:00 +0100

Authors: Abstract On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years. For these recommendations, ACIP considered information on vaccine efficacy (including data available since October 2009, on prevention of grade 2 or 3 anal intraepithelial neoplasia [AIN2/3], a precursor of anal cancer)...

Gardasil recommended for all U.S. boys

Health News - UPI.com — Fri, 23 Dec 2011 03:54:11 +0100

ATLANTA, Dec. 22 (UPI) -- Centers for Disease Control and Prevention officials recommend vaccinating all U.S. boys ages 11 or 12 with the quadrivalent human papillomavirus vaccine. (Source: Health News - UPI.com)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Female-Only HPV Vaccination Most Effective (CME/CE)

MedPage Today Pediatrics — Thu, 22 Dec 2011 17:43:11 +0100

(MedPage Today) -- Increasing vaccination for the human papillomavirus (HPV) among pre-adolescent girls is more effective than extending existing programs to include boys, according to a range of transmission models. (Source: MedPage Today Pediatrics)

Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh

Japanese Journal of Clinical Oncology — Thu, 22 Dec 2011 05:00:00 +0100

Conclusions The human papillomavirus-16/18 AS04-adjuvanted vaccine was generally well tolerated and highly immunogenic when administered to young adolescent females and could be a promising tool for the prevention and control of cervical cancer in Bangladesh. (Source: Japanese Journal of Clinical Oncology)

Adding phase to HPV vaccine policy could save lives, money

CTV Health — Thu, 22 Dec 2011 00:17:00 +0100

A new study says protecting women aged 17 to 26 against the human papillomavirus or HPV in a catch-up vaccination round would save lives -- and save millions of dollars in the process. (Source: CTV Health)

Gardasil for Boys

About.com Pediatrics — Wed, 21 Dec 2011 05:00:00 +0100

The Advisory Committee on Immunization Practices (ACIP) recommended the routine use of the quadrivalent human papillomavirus (HPV) vaccine for boys a few months ago. Those recommendations have now been formalized, as they have been published in the CDC's Morbidity and Mortality Weekly Report....Read Full Post (Source: About.com Pediatrics)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

Journal of Adolescent Health — Tue, 20 Dec 2011 18:43:29 +0100

Conclusions: Results support coadministration of HPV-16/18 vaccine with HAB vaccine in girls aged 9–15 years. The HPV-16/18 vaccine was immunogenic and generally well tolerated in 9-year-old girls. (Source: Journal of Adolescent Health)

Global human papillomavirus vaccination: can it be cost-effective?

BJOG : An International Journal of Obstetrics and Gynaecology — Tue, 20 Dec 2011 08:55:16 +0100

Authors: Crosbie E Abstract Please cite this paper as: Crosbie EJ. Global human papillomavirus vaccination: can it be cost-effective? BJOG 2012;119:125-128. PMID: 22168760 [PubMed - in process] (Source: BJOG : An International Journal of Obstetrics and Gynaecology)

Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models

PLoS Medicine — Tue, 20 Dec 2011 05:00:00 +0100

Conclusions Increasing vaccine uptake among preadolescent girls is more effective in reducing HPV infection than including boys in existing vaccination programs. As a rule, directing prophylactic immunization at the sex with the highest prevaccine prevalence results in the largest reduction of the population prevalence. Please see later in the article for the Editors' Summary (Source: PLoS Medicine)

Human Papillomavirus Vaccine and Sexual Behavior Among Adolescent and Young Women

American Journal of Preventive Medicine — Tue, 20 Dec 2011 00:13:30 +0100

Background: Vaccines to prevent certain types of human papillomavirus (HPV) and associated cancers are recommended for routine use among young women. Nationally representative reports of vaccine uptake have not explored the relationship between HPV vaccine initiation and various sexual behaviors. Purpose: Explore sexual behavior and demographic correlates of HPV vaccine initiation from a nationally representative survey of adolescent and young adult women. Methods: In 2007–2008, a total of 1243 girls/women aged 15–24 years responded to questions about receiving HPV vaccine in the National Survey of Family Growth (NSFG). In 2010, demographic and sexual behavior correlates were evaluated in bivariate and multivariate analyses by age. Results: HPV vaccine initiation was higher amon...

Gardasil boys come marching in - 4 new Gardasil deaths reported to VAERS

NaturalNews.com — Mon, 19 Dec 2011 06:00:00 +0100

God grant me the serenity to realize that government health agencies are no longer going to protect my family's health and wellbeing - the courage to stand up and say 'no' to forced vaccination and the wisdom to know the difference between coercion and compliance. Amen... (Source: NaturalNews.com)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Clinical performance assessment of five human papillomavirus DNA tests using liquid‐based cytology samples

Journal of Obstetrics and Gynaecology Research — Mon, 19 Dec 2011 05:00:00 +0100

Conclusion: All five HPV tests showed reliable results in detecting HR HPVs, high‐grade CIN, and cancer. Both LA and DNA chip tests may be useful in identifying HR HPV, especially when multiple genotypes are present. (Source: Journal of Obstetrics and Gynaecology Research)

FDA Approves Hologic's Cervista High Throughput Automation System For Cervical Cancer Screening

Health News from Medical News Today — Sun, 18 Dec 2011 08:00:00 +0100

Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus (HPV) HR test... (Source: Health News from Medical News Today)

HPV Vaccine Does Not Appear To Encourage Risky Sexual Behavior

Health News from Medical News Today — Sat, 17 Dec 2011 08:00:00 +0100

Despite some assumptions to the contrary, young women who receive recommended vaccinations to prevent human papillomavirus (HPV) infection and associated cancers do not engage in more sexually risky behavior. That is the cautious determination of a national study by The Centers for Disease Control & Prevention reported in the American Journal of Preventive Medicine. Lead study author Nicole C. Liddon, Ph.D. advised against drawing too broad a conclusion from the study, while explaining the motivation behind it... (Source: Health News from Medical News Today)

From September 2012 in the UK, the quadrivalent human papillomavirus (HPV) vaccine, Gardasil, will replace the bivalent Cervarix vaccine

PharmacoEconomics and Outcomes News — Sat, 17 Dec 2011 03:21:49 +0100

(Source: PharmacoEconomics and Outcomes News)

Global human papillomavirus vaccination: can it be cost‐effective?

BJOG: An International Journal of Obstetrics and Gynaecology — Fri, 16 Dec 2011 16:03:17 +0100

Please cite this paper as: Crosbie EJ. Global human papillomavirus vaccination: can it be cost‐effective? BJOG 2012;119:125–128. (Source: BJOG: An International Journal of Obstetrics and Gynaecology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Detecting Cervical Cancer - HPV DNA Test Is Best

Health News from Medical News Today — Fri, 16 Dec 2011 16:00:00 +0100

Final results of the POBASCAM trial reveal that for women aged 30+, the human papillomavirus (HPV) DNA test is the optimum cervical cancer screening option. The HPV DNA test prevents more cervical cancers than cytology alone, and detects lesions which cause cervical cancer earlier. Study results provide the strongest evidence to date in favor of using this test in national screening programs. The trial is published Online First in The Lancet Oncology... (Source: Health News from Medical News Today)

Human papillomavirus vaccine recombinant quadrivalent: Demyelinating disorders: case report

Reactions — Fri, 16 Dec 2011 06:55:18 +0100

(Source: Reactions)

Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations.

Anales de Pediatria — Thu, 15 Dec 2011 05:00:00 +0100

Authors: Moreno-Pérez D, Alvarez García FJ, Aristegui Fernández J, Barrio Corrales F, Cilleruelo Ortega MJ, Corretger Rauet JM, González-Hachero J, Hernández-Sampelayo Matos T, Merino Moína M, Ortigosa Del Castillo L, Ruiz-Contreras J, Abstract The Advisory Committee on Vaccines of the Spanish Association of Pediatrics (CAV-AEP) updates the immunization schedule every year, taking into account epidemiological data as well as evidence on the effectiveness and efficiency of vaccines. The present schedule includes grades of recommendation. We have graded as routine vaccinations those that the CAV-AEP believes all children should receive; as recommended those that fit the profile for universal childhood immunization and would ideally be given to all children, but that can be pri...

Management of Cervical Precancers: A Global Perspective

Hematology/Oncology Clinics of North America — Thu, 15 Dec 2011 05:00:00 +0100

The incidence and mortality of cervical cancer have decreased dramatically over the past 70 years in well-developed countries through successful screening programs using cytologic examination, followed by evaluation and treatment of high-grade precancers of the cervix. In less-well-developed countries, cervical cancer incidence and mortality remain high. However, moving forward, a combination of the human papillomavirus (HPV) vaccine, new HPV screening capability, and simple see-and-treat techniques may help to decrease the cervical cancer burden in these countries. (Source: Hematology/Oncology Clinics of North America)

Human papillomavirus infection among young adolescents in India: Impact of vaccination

Journal of Medical Virology — Wed, 14 Dec 2011 19:14:11 +0100

AbstractHigh‐risk human papillomaviruses (HR‐HPVs) are the causative agents of cervical cancer and prophylactic HPV vaccination has been recommended for adolescents but no data are available on the prevalence of HPV infection among adolescents in India. Self‐collected midstream urine samples from 940 healthy school children, aged 8–17 years, from 12 different schools in and around Noida and Delhi, India, were collected for HPV detection by PCR. Of 458 girls, 15 (3.2%) were positive for HPV and 10 (66.6%) were positive for high‐risk human papillomavirus (HR‐HPV) type16 and 2 (13.3%) for HPV 18. Of 342 boys, 7 (2.1%) were HPV positive, of which 5 (71.4%) had HPV type 6 but interestingly, none were positive for HR‐HPV types 16 or 18. Among HPV positive girls, 13 (66.6%) were >...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA.

Journal of Immunology — Wed, 14 Dec 2011 05:00:00 +0100

Authors: Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G Abstract The majority of HIV infections occur via mucosal transmission. Vaccines that induce memory T and B cells in the female genital tract may prevent the establishment and systemic dissemination of HIV. We tested the immunogenicity of a vaccine that uses human papillomavirus (HPV)-based gene transfer vectors, also called pseudovirions (PsVs), to deliver SIV genes to the vaginal epithelium. Our findings demonstrate that this vaccine platform induces gene expression in the genital tract in both cynomolgus and rhesus macaques. Intravaginal vaccination with HPV16, HPV...

[Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations.]

Anales de Pediatria — Wed, 14 Dec 2011 05:00:00 +0100

Authors: Moreno-Pérez D, Alvarez García FJ, Arístegui Fernández J, Barrio Corrales F, Cilleruelo Ortega MJ, Corretger Rauet JM, González-Hachero J, Hernández-Sampelayo Matos T, Merino Moína M, Ortigosa Del Castillo L, Ruiz-Contreras J, Abstract The Advisory Committee on Vaccines of the Spanish Association of Pediatrics (CAV-AEP) updates the immunization schedule every year, taking into account epidemiological data as well as evidence on the effectiveness and efficency of vaccines. The present schedule includes grades of recommendation. We have graded as routine vaccinations those that the CAV-AEP believes all children should receive; as recommended those that fit the profile for universal childhood immunization and would ideally be given to all children, but that can be pri...

HPV Vaccine Does Not Appear to Encourage Risky Sexual Behavior

Health Behavior News Service — Tue, 13 Dec 2011 14:41:38 +0100

12/13/2011, American Journal of Preventive Medicine, Young women who receive recommended vaccinations to prevent human papillomavirus (HPV) infection and associated cancers do not engage in more sexually risky behavior, according to a study in the American Journal of Preventive Medicine. (Source: Health Behavior News Service)

Study confirms that many survivors of breast cancer chemotherapy treatments suffer from brain damage

NaturalNews.com — Tue, 13 Dec 2011 00:00:00 +0100

Just like they often do in response to the numerous health problems brought about by things like Morgellons Disease and the HPV vaccines Gardasil and Cervarix, doctors commonly deny that the cognitive problems reported by breast cancer patients following chemotherapy... (Source: NaturalNews.com)

The Contribution of NT‐gp96 as an Adjuvant for Increasing HPV16 E7‐Specific Immunity in C57BL /6 Mouse Model

Scandinavian Journal of Immunology — Fri, 09 Dec 2011 23:47:43 +0100

In this study, the recombinant HPV16 E7 and E7 linked to NT‐gp96 (E7‐NT‐gp96) proteins were generated in prokaryotic expression system. Mice were vaccinated twice with this recombinant proteins and the immunogenicity of the fusion protein was determined. The preventive efficacy of E7‐NT‐gp96 fusion protein was also evaluated and compared to E7 protein after challenging with cancerous TC‐1 cell line. In vitro re‐stimulated splenocytes of mice vaccinated with rE7‐NT‐gp96 protein induced higher IFN‐γ response in comparison with E7 protein immunization. Moreover, immunization with E7‐NT‐gp96 protein displayed low but stable humoral responses at post‐challenge time. The data showed that vaccination with fused E7‐NT‐gp96 protein delayed the tumour occurrence and gr...

MedWorm Sponsor Message: Find the best January Sales in the UK.

The immunogenicity of quadrivalent hpv (types 6/11/16/18) vaccine in males aged 16-26.

Clinical and Vaccine Immunology — Wed, 07 Dec 2011 05:00:00 +0100

We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males.Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1, and at months 7, 24 and 36 post-vaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex Immunoassay.Almost all subjects (97.4-99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9% and 57.0% of subjects were still seropositive for HPV 6, 11, 16 and 18, respectively. For all vaccine HPV types, Black subjects had significantly higher antibody titers at month 7 compared with both Caucasian and Asian subjects....

[Correspondence] HPV vaccine in Rwanda: different disease, same double standard

LANCET — Sat, 03 Dec 2011 05:00:00 +0100

In a Correspondence letter (July 23, p 315) regarding Rwanda's human papillomavirus (HPV) vaccine roll-out, Nobila Ouedraogo and colleagues express “serious doubts that [a national HPV immunisation programme] is in the best interest of the people”. Are the 330 000 Rwandan girls who will be vaccinated against a highly prevalent, oncogenic virus for free during the first phase of this programme not regarded as “the people”? (Source: LANCET)

Adolescent Vaccination-Coverage Levels in the United States: 2006-2009

PEDIATRICS — Thu, 01 Dec 2011 05:00:00 +0100

CONCLUSIONS: Adolescent vaccination coverage is increasing but could be improved. Strategies are needed to increase parental knowledge about adolescent vaccines and improve provider recommendation and administration of all vaccines during the same visit. (Source: PEDIATRICS)

Prevalence of abnormalities influences cytologists' error rates in screening for cervical cancer.

Archives of Pathology and Laboratory Medicine — Thu, 01 Dec 2011 05:00:00 +0100

Conclusions.-These results provide the first evidence, to our knowledge, that experts are not immune to the effects of prevalence even with stimuli from their domain of expertise. Prevalence is a factor to consider in screening for disease by human observers and has significant implications for cytology-based cervical cancer screening in the post-human papillomavirus vaccine era, when prevalence rates of high-grade lesions in the population are expected to decline. PMID: 22129183 [PubMed - in process] (Source: Archives of Pathology and Laboratory Medicine)

Human papillomavirus infection, vaccination, and cervical cancer communication: the protection dilemma faced by women in southern appalachia.

Women and Health — Wed, 30 Nov 2011 05:00:00 +0100

Authors: Hutson SP, Dorgan KA, Duvall KL, Garrett LH Abstract Human papillomavirus is the most frequently occurring sexually transmitted infection and has been recognized as the necessary cause of cervical cancer. Understanding the shift in public awareness caused by recent changes to cervical prevention is critical to addressing cervical cancer disparities in Appalachia. Since the human papillomavirus vaccine was approved for prevention, little data have been collected regarding human papillomavirus risk assessment and vaccine perceptions among Appalachian women. The purpose of the authors in this study was to investigate communication and cultural issues via a social scripting framework that could influence human papillomavirus vaccine uptake among southern Appalachian women; and...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Knowledge, attitudes of human papillomavirus vaccine, and intention to obtain vaccine among korean female undergraduate students.

Women and Health — Wed, 30 Nov 2011 05:00:00 +0100

Authors: Kang HY, Kim JS Abstract The purpose of this study was to examine knowledge about the human papillomavirus and attitudes toward human papillomavirus and human papillomavirus vaccination among Korean female undergraduate students. Moreover, this study sought to identify factors associated with intention to obtain the human papillomavirus vaccine. A cross-sectional study was conducted with 297 Korean female undergraduate students. Data were collected using a self-administered questionnaire. Collected data were analyzed with descriptive statistics, t-test or ANOVA, and stepwise multiple regression analysis. Only 37.8% of the participants were aware of human papillomavirus. The percentage of correct answers for knowledge about human papillomavirus was 40.6%. Factors associated...

HPV Vaccination Change Is A Good Thing, Says British Dental Health Foundation

Health News from Medical News Today — Tue, 29 Nov 2011 15:00:00 +0100

The Government's plan to switch its Human Papilloma Virus (HPV) vaccination from "Cervarix" to Gardasil" from Sep. 2012, has been welcomed by the British Dental Health Foundation. The leading oral health charity believes that the novel vaccine will deliver increased health benefits and prevent genital warts. In 2010, 75,000 individuals were diagnosed with genital warts, according to the Health Protection Agency. Already, the vaccination program helps save the lives of approximately 400 individuals with cervical cancer each year... (Source: Health News from Medical News Today)

Global health organization to purchase millions of toxic HPV vaccines to administer to women and girls in third-world countries

NaturalNews.com — Tue, 29 Nov 2011 07:00:00 +0100

(NaturalNews) At its recent board meeting in Bangladesh, the GAVI Alliance, formerly known as the Global Alliance for Vaccines and Immunizations, announced plans to bring the deadly human papillomavirus (HPV) vaccines Gardasil (Merck and Co.) and Cervarix (GlaxoSmithKline) into the third world. A pro-vaccination group backed by the World Bank, UNICEF, the Bill and Melinda Gates Foundation, and the vaccine industry, GAVI's stated goal is to vaccinate 240 million children by 2015.As many as two million women and girls in nine unidentified developing countries could soon receive one of the two HPV vaccines, even though HPV is potentially linked to only one percent, of all cervical cancers, according to some reports (http://washingtonexaminer.com/node/104241). The US Food and Drug Administrati...

Population‐based human papillomavirus 16,18, 6 and 11 DNA positivity and seropositivity in chinese women

International Journal of Cancer — Mon, 28 Nov 2011 05:00:00 +0100

AbstractTo optimize HPV vaccination implementation at the population‐level in China, data are needed on age‐specific HPV 16, 18, 6 and 11 prevalence. This cross‐sectional, population‐based study evaluated the age‐ and type‐specific HPV 16, 18, 6 and 11 prevalence of DNA and serum antibodies among women in China. From July 2006 to April 2007, 17 to 54‐year‐old women from three rural provinces (Xinjiang, Shanxi, and Henan) and two cities (Beijing and Shanghai) provided cervical exfoliated cells for HPV DNA and liquid‐based cervical cytology (SurePath). High and low‐risk HPV types were detected with HC‐II (Qiagen), with genotyping of HPV‐positive samples using Linear Array (Roche). HPV 16, 18, 6, and 11 serum antibodies were detected using a Luminex‐based, competitiv...

Population‐based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women

International Journal of Cancer — Mon, 28 Nov 2011 05:00:00 +0100

AbstractTo optimize HPV vaccination implementation at the population‐level in China, data are needed on age‐specific HPV 16, 18, 6 and 11 prevalence. This cross‐sectional, population‐based study evaluated the age‐ and type‐specific HPV 16, 18, 6 and 11 prevalence of DNA and serum antibodies among women in China. From July 2006 to April 2007, 17–54 year old women from three rural provinces (Xinjiang, Shanxi and Henan) and two cities (Beijing and Shanghai) provided cervical exfoliated cells for HPV DNA and liquid‐based cervical cytology (SurePath). High‐ and low‐risk HPV types were detected with HC‐II (Qiagen), with genotyping of HPV‐positive samples using Linear Array (Roche). HPV 16, 18, 6 and 11 serum antibodies were detected using a Luminex‐based, competitive im...

MedWorm Sponsor Message: Find the best January Sales in the UK.

UK switches HPV vaccine supplier

Pharmaceutical Technology — Fri, 25 Nov 2011 18:44:05 +0100

The UK will switch to using Merck's Gardasil vaccine instead of GlaxoSmithKline's rival product Cervarix to prevent girls from contracting the HPV virus, which can cause cervical cancer.Post to:Delicious Digg reddit Facebook StumbleUpon (Source: Pharmaceutical Technology)

Gardasil chosen for next year's HPV vaccination programme

OnMedica Latest News — Fri, 25 Nov 2011 05:00:00 +0100

Quadrivalent vaccine will tackle genital warts as well as cervical cancerRelated items from OnMedicaParents unsure of HPV vaccine for daughters One or two doses of HPV jab may be enoughBabies aged 2-3 months to a year vulnerable to measlesAt-risk groups told flu jab doesn’t give you fluMeasles programme must be stepped-up (Source: OnMedica Latest News)

CAS communication: HPV immunisation programme - change of supply to Gardasil® from September 2012

NeLM - News — Fri, 25 Nov 2011 05:00:00 +0100

Source: CAS Area: News The Director of Immunisation has issued a communication informing of a change in the choice of human papillomavirus (HPV) vaccine for the national HPV immunisation programme for girls in school year 8 (aged 12 to 13 years). Following a competitive tendering exercise, the Department of Health (DH) will be providing Gardasil® from September 2012. Unlike the current vaccine in use (Cervarix), Gardasil also protects against HPV types 6 and 11, which cause nearly all genital warts. Figures from the Health Protection Agency show that 75,000 people were diagnosed with genital warts in 2010. According to a BBC report, some sexual health experts had criticised the DH decision in 2008 to opt for Cervarix, the cheaper of the two vaccines. A consultant in sexual hea...

Cervical cancer vaccine u-turn: Gardasil to replace rival Cervarix

the Mail online | Health — Thu, 24 Nov 2011 22:24:26 +0100

Cervarix, a vaccine that protects cervical cancer, will be replaced by Gardasil which also prevents up to 90 per cent of genital warts, say health chiefs. (Source: the Mail online | Health)

UK switches to Merck's Gardasil for HPV vaccination

Reuters: Health — Thu, 24 Nov 2011 20:38:52 +0100

LONDON (Reuters) - Britain is to stop using GlaxoSmithKline's cervical cancer vaccine Cervarix from next September and will instead offer girls Merck & Co's rival product Gardasil. (Source: Reuters: Health)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Genital warts vaccination to be offered to schoolgirls

Guardian Unlimited Science — Thu, 24 Nov 2011 20:38:30 +0100

Doctors welcome news and predict that genital warts could be eradicated among heterosexuals within 20 yearsSchoolgirls across the UK will be offered immunisation against genital warts, one of the most common sexually transmitted infections, in a move welcomed by doctors.It will expand the existing vaccination against cervical cancer for 12- and 13-year-olds.The change will take place at the start of the next school year in August and September 2012. All 12- and 13-year-old schoolgirls will be offered a vaccine called Gardasil, which protects against the two strains of the human papilloma virus (HPV) that cause 70% of cervical cancers and also two other strains that produce 90% of genital warts.It will replace Cervarix, which has been used since immunisation began in 2008 but only offers pr...

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.

Gynecologic Oncology — Wed, 23 Nov 2011 05:00:00 +0100

CONCLUSIONS: HPV 16 and 18 accounted together for a 72.4% of positive cases, with no statistically significant changes in their relative contributions over the last decades. In 94% of cervical adenocarcinomas we identified at least one of the two HPV types included in the current vaccines (HPV 16/18). Results suggest a major impact of HPV vaccines on reduction of ICC burden in Spain in the HPV vaccinated cohorts. PMID: 22119990 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)

The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions

Cancer Causes and Control — Tue, 22 Nov 2011 17:57:58 +0100

Abstract The following paper describes a collaboration between the Centers for Disease Control and Prevention and five Emerging Infections Program sites to develop a comprehensive population-based approach to monitoring human papillomavirus (HPV) vaccine impact on cervical cancer precursors and associated HPV genotypes. The process of establishing this novel monitoring system is described, and development details such as enumeration of sources for reporting cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ, approaches to case ascertainment, electronic reporting, and HPV typing are outlined. Implementation of a feasible and sustainable surveillance system for HPV-associated cervical precancers will enable evaluation of the direct impact of HPV vaccination. ...

[Correspondence] Assessment of herd immunity from human papillomavirus vaccination

The Lancet Infectious Diseases — Tue, 22 Nov 2011 11:05:03 +0100

We read with interest the Article by Basil Donovan and colleagues, who presented early evidence of reduced morbidity of genital warts after the introduction of quadrivalent human papillomavirus (HPV) vaccination. Their pooled analysis of sentinel surveillance data from eight sexual health service clinics across Australia suggested a stable incidence of genital warts in the prevaccination period followed by a highly significant downwards trend (p<0·0001) since mid-2007, when the quadrivalent vaccine became available to young Australian women at no cost. (Source: The Lancet Infectious Diseases)

[Correspondence] Assessment of herd immunity from human papillomavirus vaccination – Authors' reply

The Lancet Infectious Diseases — Tue, 22 Nov 2011 11:05:03 +0100

Johannes Bogaards' and Johannes Berkhof's suggested method of analysis is perfectly valid. However, they have used the data for all heterosexual men (table 1 and figure 2C in our Article) rather than for younger heterosexual men (12–26 years old; figure 2D). This younger age group was the only group that seemed to have benefited from a herd effect, and in this group the prevalence of genital warts did not seem to be decreasing before vaccination began. Before we submitted our original report we asked several colleagues about the best way to analyse our data, and no two statisticians suggested the same method. (Source: The Lancet Infectious Diseases)

MedWorm Sponsor Message: Find the best January Sales in the UK.

US patent awarded for Rochester's pioneering HPV vaccine work

EurekAlert! - Medicine and Health — Tue, 22 Nov 2011 05:00:00 +0100

(University of Rochester Medical Center) The University of Rochester has been awarded a US patent for research essential to both human papillomavirus vaccines on the market. The patent is for the creation of virus-like particles that mimic HPV 16, the type of HPV that causes the majority of all cancers related to HPV. (Source: EurekAlert! - Medicine and Health)

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

Sexually Transmitted Infections — Tue, 22 Nov 2011 05:00:00 +0100

Conclusion The dramatic decline and near disappearance of GW in women and men under 21 years of age, 4 years after commencing this programme, suggest that the basic reproductive rate has fallen below one. (Source: Sexually Transmitted Infections)

Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring

Sexually Transmitted Infections — Tue, 22 Nov 2011 05:00:00 +0100

Conclusions Some women were willing to participate in anonymised postal testing. However, the low uptake means that HPV prevalence results are difficult to interpret for ongoing surveillance. Monitoring HPV vaccine impact outwith the cervical screening programme remains challenging. (Source: Sexually Transmitted Infections)

Cancer vaccines.

Primary Care — Mon, 21 Nov 2011 14:25:02 +0100

Authors: Chambers CV Abstract The term cancer vaccines encompasses 2 different types of vaccines. Prophylactic vaccines block infection by viruses that can alter host DNA and result in cancer. The hepatitis B vaccine and the human papillomavirus vaccines are examples of prophylactic vaccines that can prevent cancer from developing. More recently, therapeutic vaccines have been developed and used as adjunctive therapy in patients who have already been diagnosed with cancer. Therapeutic vaccines stimulate the host's immune system to recognize cancer cells as foreign and to attack them. Most of the therapeutic vaccines being studied are used in combination with other forms of cancer therapy. PMID: 22094141 [PubMed - in process] (Source: Primary Care)

Worldwide burden of cervical cancer in 2008

Annals of Oncology — Mon, 21 Nov 2011 05:00:00 +0100

Conclusions: In spite of effective screening methods, cervical cancer continues to be a major public health problem. New methodologies of cervical cancer prevention should be made available and accessible for women of all countries through well-organised programmes. (Source: Annals of Oncology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics.

Vaccine — Sat, 19 Nov 2011 05:00:00 +0100

CONCLUSIONS: In four urban safety-net clinics, HPV initiation rates paralleled 2008 national rates. The correlation of HPV initiation with other adolescent vaccines underscores the importance of reviewing vaccination status at every health care visit. HPV vaccine uptake in safety-net clinics should continue to be monitored to understand impact on cervical cancer disparities. PMID: 22108490 [PubMed - as supplied by publisher] (Source: Vaccine)

CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice

Cancer Immunology, Immunotherapy — Fri, 18 Nov 2011 06:58:22 +0100

Abstract Considerable effort has been put into targeting tumors through therapeutic vaccination using dendritic cell-, DNA-, protein-, or peptide-based vaccines. Purified peptides and proteins are generally not immunogenic and need to be administered with an adjuvant that will trigger an appropriate immune response. Safe adjuvants that favor induction of tumor reactive CD8+ T cells with the capacity to directly kill tumor cells are therefore a high priority. We have previously reported on the effect and mechanism of a cationic adjuvant formulation, CAF01, which incorporates synthetic mycobacterial cord factor and primes protective Th1, Th17, and antibody responses in animal models of bacterial, viral, and parasitic infections. The CAF01 adjuvant is currently in clinical tri...

HPV infections: Can they be eradicated using nanotechnology?

Nanomedicine : Nanotechnology, Biology, and Medicine — Fri, 18 Nov 2011 05:00:00 +0100

Abstract: Human papillomavirus (HPV) infections are considered the most common sexually transmitted diseases, with more than 450 million people worldwide infected. HPVs can cause anogenital warts and neoplasias. One prevalent cancer type caused by HPV (mostly type 16 and 18) is cervical intraepithelial neoplasia (CIN). Nanotechnology tools employed in the development of vaccines and a noninvasive treatment may provide a significant advancement in the global combat against this disease. (Source: Nanomedicine : Nanotechnology, Biology, and Medicine)

Africa: Steps Taken to Inrtroduce Vaccines Against Cervical Cancer, Rubella

AllAfrica News: Health and Medicine — Thu, 17 Nov 2011 21:08:18 +0100

Responding to demand from developing countries, the GAVI Alliance will take the first steps towards the introduction of Human papillomavirus (HPV) and rubella vaccines in developing countries, the GAVI Board announced on Thursday. (Source: AllAfrica News: Health and Medicine)

A CDC panel has recommended the human papillomavirus (HPV) vaccine for boys aged 11-12 years

PharmacoEconomics and Outcomes News — Thu, 17 Nov 2011 18:01:00 +0100

(Source: PharmacoEconomics and Outcomes News)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Massive HPV And Rubella Vaccine Campaign For Girls And Women Globally

Health News from Medical News Today — Thu, 17 Nov 2011 18:00:00 +0100

The GAVI Alliance Board is to move towards the vaccination of up to two million girls and women in nine countries against HPV (human papillomavirus) and rubella over the next four years. GAVI is a charity which aims to save children's lives and protect people's health "by increasing access to immunization in poor countries"... (Source: Health News from Medical News Today)

GAVI takes first steps to introduce vaccines against cervical cancer and rubella

WHO Maternal, Newborn and Child Health — Thu, 17 Nov 2011 09:29:00 +0100

17 NOVEMBER 2011 | DHAKA – Responding to demand from developing countries, the GAVI Alliance will take the first steps towards the introduction of human papillomavirus and rubella vaccines, the GAVI Board has announced. (Source: WHO Maternal, Newborn and Child Health)

Make sure teens get all vaccines at once

Modern Medicine Contemporary Pediatrics — Thu, 17 Nov 2011 05:00:00 +0100

Teenagers are much more likely to be up-to-date on their immunizations if all vaccinations are administered at 1 visit. Pediatricians need to do more to make that happen. That’s the recommendation of a study that found that coverage with the meningococcal conjugate vaccine; the tetanus, diphtheria, and acellular pertussis vaccine; and the human papillomavirus vaccine was increasing for adolescents but could be improved. What do researchers recommend you do to enhance vaccination rates? (Source: Modern Medicine Contemporary Pediatrics)

Information Channels Associated with Awareness of Human Papillomavirus Infections and Vaccination among Latino Immigrants from Safety Net Clinics

Journal of Immigrant and Minority Health — Wed, 16 Nov 2011 16:48:15 +0100

We report on information channels associated with awareness about human papillomavirus (HPV) among immigrant Central and South American Latinos. We conducted a survey of 1,334 Latino ≥ 21 years attending safety-net clinics in 2007–2008. Logistic regression analyses evaluated associations with HPV awareness. Forty-eight percent were aware of HPV infection and 40% were aware of the vaccine. Spanish television (38%) and providers (23%) were the primary HPV information sources. Infection awareness was associated with internet use (OR 1.47; 95% CI 1.10–1.96) and self-efficacy to find health information (OR 1.19; 95% CI 1.08–1.30). Vaccine awareness was associated with media use for health information (OR 1.27; 95% CI 1.09–1.49) and internet use (OR 1.59; 95% CI 1....

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

High-risk HPV infection after five years in a population-based cohort of Chilean women

Infectious Agents and Cancer — Wed, 16 Nov 2011 05:00:00 +0100

Conclusions: HR-HPV prevalence increased in the study population. All HR-HPV infections in women 30 years. (Source: Infectious Agents and Cancer)

Human papillomavirus genotype distribution in Madrid and correlation with cytological data

BMC Infectious Diseases — Tue, 15 Nov 2011 05:00:00 +0100

Conclusions: HPV16 was the most frequent genotype in our area, followed by HPV 53 and 31, with a low prevalence of HPV 18 even in HSILs. The frequency of genotypes 16, 52 and 58 increased significantly from ASCUS to HSILs. Although a vaccine against HPV16 and 18 could theoretically prevent approximately 50% of HSILs, genotypes not covered by the vaccine are frequent in our population. Knowledge of the epidemiological distribution is necessary to predict the effect of vaccines on incidence of infection and evaluate cross-protection from current vaccines against infection with other types. (Source: BMC Infectious Diseases)

Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants

BMC Biotechnology - Latest articles — Tue, 15 Nov 2011 05:00:00 +0100

Conclusions: In this study, we report for the first time the transient expression and the self-assembly of a chimeric HPV-16 L1 bearing the M2e influenza epitope in plants, representing also the first record of a successful expression of chimeric HPV-16 L1 carrying an epitope of a heterologous virus in plants. This study further confirms the usefulness of human papillomavirus particles as carriers of exogenous epitopes and their potential relevance for the production in plants of monovalent or multivalent vaccines. (Source: BMC Biotechnology - Latest articles)

Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women

Infectious Agents and Cancer — Mon, 14 Nov 2011 05:00:00 +0100

Conclusions: In women with no evidence of cytological abnormalities, the most prevalent genotypes were HPV58 with HPV16, 35, 52, 66 and 73 occurring equally. Although numerical constraints limit inference, findings that 91% of ICC harbor only a small number of HPV genotypes suggests that prevention efforts including vaccine development or adjuvant screening should focus on these genotypes. (Source: Infectious Agents and Cancer)

Safety of Quadrivalent Human Papillomavirus Vaccine

Journal of Internal Medicine — Fri, 11 Nov 2011 05:00:00 +0100

(Source: Journal of Internal Medicine)

MedWorm Sponsor Message: Find the best January Sales in the UK.

HPV Might Lower Cervical Cancer Rate Considerably - Screening Programs Should Be Changed

Health News from Medical News Today — Thu, 10 Nov 2011 13:00:00 +0100

According to findings of two investigations published Online First in The Lancet Oncology, the bivalent human papillomavirus (HPV) vaccine (GlaxoSmithKline, Cervarix) provides exceptional protection against the more serious immediate precursor to invasive cervical cancer (ICC). It is particularly effective in protecting young girls prior to becoming sexually active. The studies reveal that the HPV vaccine also partially protects against 4 other cancer-causing HPV types, which are not targeted by the formulation... (Source: Health News from Medical News Today)

Interferons as Therapeutic Agents for Infectious Diseases

Infectious Diseases Clinics of North America — Thu, 10 Nov 2011 12:09:33 +0100

This article explains the rationale for development of interferons as therapeutic agents, and describes commercial products available today. It also provides a summary of studies that have been performed with interferons for use as exogenous biological response modifiers in viral infections. Overall, the best data exist for treatment of viral hepatitis B and C, for which interferons are a cornerstone of therapy. Although infections with human papillomavirus and common cold viruses sometimes respond favorably to interferons, their outcomes are far from ideal. Finally, the role of interferons as vaccine adjuvants is still being explored but could be promising. (Source: Infectious Diseases Clinics of North America)

HPV Vaccine Protects Against Cervical Cancer Precursors (CME/CE)

MedPage Today Hematology/Oncology — Thu, 10 Nov 2011 10:13:13 +0100

(MedPage Today) -- The human papillomavirus (HPV) vaccine offered excellent protection against the precursors of invasive cervical cancer, plus partial protection against four nonvaccine oncogenic HPV types, according to two studies. (Source: MedPage Today Hematology/Oncology)

HPV Vaccine Greatly Reduces the Incidence of Cervical Cancer

Medical Headlines From Ivanhoe.com — Thu, 10 Nov 2011 05:00:00 +0100

(Ivanhoe Newswire) – The HPV (human papillomavirus) vaccine sufficiently protects against the more serious immediate precursor to invasive cervical cancer (ICC), particularly when given to young adolescent girls before they become sexually active, according to this study. (Source: Medical Headlines From Ivanhoe.com)

Prevalence of Human Papillomavirus Infection in Women in Benin, West Africa

Virology Journal — Thu, 10 Nov 2011 05:00:00 +0100

Conclusions: This study provides the first estimates of the prevalence of HPV and type-specific distribution among women from Benin and demonstrates that the epidemiology of HPV infection in Benin is different from that of other world regions. Specific area vaccinations may be needed to prevent cervical cancer and the other HPV-related diseases. (Source: Virology Journal)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types

GSK news — Wed, 09 Nov 2011 09:16:01 +0100

An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection against this type of lesion are considered the most stringent evidence of potential cervical cancer prevention. (Source: GSK news)

ACIP Recommends HPV Vaccination of Boys

Blogged_Arteries — Wed, 09 Nov 2011 06:00:00 +0100

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) now recommends routine vaccination of boys aged 11 to 12 with 3-doses of HPV4 to protect against Human Papilloma Virus (HPV). (Source: Blogged_Arteries)

Two 4-year end-of-study analyses evaluating Cervarix against grade 3 or greater cervical intraepithelial neoplasia and other non-vaccine oncogenic HPV types

NeLM - News — Wed, 09 Nov 2011 05:00:00 +0100

Source: Lancet Oncology Area: News The Lancet Oncology has featured two 4-year end-of-study analyses early online in which the efficacy of the HPV-16/18 adjuvanted vaccine was evaluated for: . CIN3+ and adenocarcinoma in situ (AIS) in the PApilloma TRIal against Cancer In young Adults (PATRICIA trial), and . Outcomes of other non-vaccine oncogenic HPV types [Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy against CIN3+, the immediate precursor to invasive cervical cancer, is more difficult to measure because of its lower incidence, but provides the most stringent evidence of potential cancer prevention.] The PATRICIA trial h...

BMJ news item: Organisations challenge basis for US recommending HPV vaccine for boys

NeLM - News — Tue, 08 Nov 2011 05:00:00 +0100

Source: BMJ Area: News According to a news item published in the British Medical Journal (BMJ), the recommendation by a Committee in the US that the human papillomavirus (HPV) vaccine be routinely given to boys aged 11-12 years has been challenged by two medical organisations who raise questions about the financial interests of guideline writers, politicians, and organisations promoting the vaccine. (Source: NeLM - News)